Want to join the conversation?
$AGN, a global pharmaceutical company, announces the launch of a generic version of Janssen's INVEGA (paliperidone extended-release tablets) in the U.S. $AGN is the first to receive the FDA approval for generic version of INVEGA. INVEGA extended-release tablets are used for the treatment of schizophrenia in adults and adolescents.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.